Clinical and Practical Psychopharmacology
Page 2
Clinical and Practical Psychopharmacology
Using Percentiles to Understand Standardized Mean Difference as a Measure of Effect Size
August 7, 2023
Chittaranjan Andrade, MD, explains the use of SMDs as a measure of effect size. A recent meta-analysis of the effect of ChEIs on hallucinations and delusions in Alzheimer and…
Clinical and Practical Psychopharmacology
ChEIs for Delusions and Hallucinations in Alzheimer Disease and Parkinson Disease: Significant Benefits?
July 31, 2023
Chittaranjan Andrade, MD, takes a closer look at a recent meta-analysis indicating that donepezil, rivastigmine, and galantamine lessened both delusions and hallucinations in Alzheimer disease and Parkinson disease.
Clinical and Practical Psychopharmacology
Gestational Exposure to Benzodiazepines and Z-Hypnotics and Risk of Adverse Pregnancy Outcomes
April 3, 2023
Chittaranjan Andrade, MD, discusses recent studies on exposure to benzodiazepines and hypnotics and risk of major congenital malformation and other adverse pregnancy outcomes.
Clinical and Practical Psychopharmacology
Prolactin, Antipsychotics, and Fracture Risk
January 30, 2023
Fracture risk associated with antipsychotics may be related to whether they increase prolactin. If long-term treatment with prolactin-raising agents is necessary, prolactin levels should be regularly monitored.
Clinical and Practical Psychopharmacology
How to Critically Read a Study of Adverse Outcomes With Antidepressant Use
December 7, 2022
Chittaranjan Andrade, MD, explains how to think critically about a study covered in the media. Concepts include confounding by indication, regression, and how to deal with confounding.
